{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:36:52Z","timestamp":1740109012996,"version":"3.37.3"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T00:00:00Z","timestamp":1710288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T00:00:00Z","timestamp":1710288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","award":["PHRC 2011-037"],"award-info":[{"award-number":["PHRC 2011-037"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-024-04842-4","type":"journal-article","created":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T20:33:14Z","timestamp":1710361994000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Perioperative chemotherapy in bladder cancer: the more cisplatin, the best survival?"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5920-4468","authenticated-orcid":false,"given":"Christian","family":"Pfister","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentin","family":"Harter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Allory","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Culine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,13]]},"reference":[{"key":"4842_CR1","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/NEJMoa022148","volume":"349","author":"HB Grossman","year":"2003","unstructured":"Grossman HB, Natale RB, Tangen CM et al (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859\u2013866","journal-title":"N Engl J Med"},{"key":"4842_CR2","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","volume":"29","author":"International collaboration of trialists","year":"2011","unstructured":"International collaboration of trialists (2011) International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 29:2171\u20132177","journal-title":"J Clin Oncol"},{"key":"4842_CR3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.eururo.2021.09.028","volume":"81","author":"Advanced Bladder Cancer (ABC) Meta-analysis Collaborators Group","year":"2022","unstructured":"Advanced Bladder Cancer (ABC) Meta-analysis Collaborators Group (2022) Adjuvant chemotherapy for muscle invasive bladder cancer: a systematic review and meta-analysis of individual participant data from randomized controlled trials. Eur Urol 81:50\u201361","journal-title":"Eur Urol"},{"key":"4842_CR4","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1002\/cncr.29387","volume":"121","author":"MD Galsky","year":"2015","unstructured":"Galsky MD, Pal SK, Chowdhury S et al (2015) Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer 121:2586\u20132593","journal-title":"Cancer"},{"key":"4842_CR5","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.juro.2017.12.062","volume":"199","author":"H Zargar","year":"2018","unstructured":"Zargar H, Shah JB, van Rhijn BW et al (2018) Neoadjuvant dose dense MVAC versus gemcitabine and cisplatin in patients with cT3-4aN0M0 bladder cancer treated with radical cystectomy. J Urol 199:1452\u20131458","journal-title":"J Urol"},{"key":"4842_CR6","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1200\/JCO.2013.52.4785","volume":"32","author":"TK Choueiri","year":"2014","unstructured":"Choueiri TK, Jacobus S, Bellmunt J et al (2014) Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol 32:1882\u20131894","journal-title":"J Clin Oncol"},{"key":"4842_CR7","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1200\/JCO.2013.53.2465","volume":"32","author":"ER Plimack","year":"2014","unstructured":"Plimack ER, Hoffman-Censits JH, Viterbo R et al (2014) Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol 32:1895\u20131901","journal-title":"J Clin Oncol"},{"key":"4842_CR8","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.eururo.2020.08.024","volume":"79","author":"C Pfister","year":"2021","unstructured":"Pfister C, Gravis G, Flechon A et al (2021) Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin, or gemcitabine and cisplatin as perioperative chemotherapy for patients with muscle-invasive bladder cancer. Analysis of the GETUG-AFU V05 VESPER trial secondary endpoints: chemotherapy toxicity and pathological responses. Eur Urol 79:214\u2013221","journal-title":"Eur Urol"},{"key":"4842_CR9","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.21.02051","volume":"40","author":"C Pfister","year":"2022","unstructured":"Pfister C, Gravis G, Flechon A et al (2022) Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: results of the GETUG-AFU V05 VESPER trial. J Clin Oncol 40:2013\u20132022","journal-title":"J Clin Oncol"},{"issue":"23","key":"4842_CR10","doi-asserted-by":"publisher","first-page":"00587","DOI":"10.1016\/S1470-2045(23)00587-9","volume":"S1470\u20132045","author":"C Pfister","year":"2023","unstructured":"Pfister C, Gravis G, Flechon A et al (2023) Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle invasive bladder cancer (VESPER): survival endpoints in an open-label, randomized, phase 3 study. Lancet Oncol S1470\u20132045(23):00587\u201300589. https:\/\/doi.org\/10.1016\/S1470-2045(23)00587-9","journal-title":"Lancet Oncol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-04842-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-024-04842-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-04842-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T21:22:56Z","timestamp":1735852976000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-024-04842-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,13]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4842"],"URL":"https:\/\/doi.org\/10.1007\/s00345-024-04842-4","relation":{},"ISSN":["1433-8726"],"issn-type":[{"type":"electronic","value":"1433-8726"}],"subject":[],"published":{"date-parts":[[2024,3,13]]},"assertion":[{"value":"20 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare with the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The different authors also confirm that there is no conflict of interest or extra institutional funding, in particular that provided by commercial sources. The GETUG\/AFU V05 VESPER randomized phase III study was supported by a grant from the French National Cancer Institute (PHRC 2011-037).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"140"}}